MTVA
MetaVia Inc.

14,717
Mkt Cap
$16.89M
Volume
1.44M
52W High
$30.25
52W Low
$6.05
PE Ratio
-5.39
MTVA Fundamentals
Price
$14.10
Prev Close
$7.32
Open
$7.70
50D MA
$9.86
Beta
1.00
Avg. Volume
336,890.87
EPS (Annual)
-$3.56
P/B
27.98
Rev/Employee
$0.00
Loading...
Loading...
MetaVia, Inc. is a clinical-stage biotechnology company, which engages in developing and commercializing multi-modal disease-modifying therapies. Its pipeline includes ANA001, a proprietary oral niclosamide formulation, Gemcabene, which is assessed as an acute indication for COVID-19, NB-01, a treatment for painful diabetic neuropathy, and NB-02, which has the potential to treat the symptoms of cognitive impairment and modify the progression of neurodegenerative diseases. The company was founded on October 30, 2014 and is headquartered in Cambridge, MA.
Sector:
Health Technology
Industry:
Biotechnology
Employees:
9

Frequently Asked Questions

What is Market Cap of MetaVia Inc.?
What is the 52-week high for MetaVia Inc.?
What is the 52-week low for MetaVia Inc.?
What is MetaVia Inc. stock price today?
What was MetaVia Inc. stock price yesterday?
What is the PE ratio of MetaVia Inc.?
What is the Price-to-Book ratio of MetaVia Inc.?
What is the 50-day moving average of MetaVia Inc.?
How many employess does MetaVia Inc. has?

Latest MTVA News

View

Advertisement|Remove ads.

Advertisement|Remove ads.